January 27, 2015 7:29 AM ET

Pharmaceuticals

Company Overview of Intersect ENT, Inc.

Company Overview

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug-eluting implants for patients undergoing sinus surgery to treat chronic sinusitis. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November, 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.

1555 Adams Drive

Menlo Park, CA 94025

United States

Founded in 2003

179 Employees

Phone:

650-641-2100

Fax:

866-736-1251

Key Executives for Intersect ENT, Inc.

Chief Executive Officer
Age: 44
Total Annual Compensation: $334.8K
Chief Operating Officer and Senior Vice President
Age: 52
Total Annual Compensation: $293.2K
Vice President of Sales
Age: 44
Total Annual Compensation: $154.5K
Compensation as of Fiscal Year 2013.

Intersect ENT, Inc. Key Developments

Intersect ENT, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Year Ended December 31, 2014

Intersect ENT, Inc. announced preliminary unaudited financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company expected to report revenue in the range of $13.2 to $13.4 million, an increase of approximately 91% over the fourth quarter of 2013. For the year end, the company expects to report revenue in the range of $38.4 to $38.6 million.

Intersect ENT, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 10:00 AM

Intersect ENT, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 10:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Lisa D. Earnhardt, Chief Executive Officer, President and Director.

Intersect ENT, Inc. Announces Board Changes, Effective December 15, 2014

On December 8, 2014, Rick D. Anderson tendered his resignation as a member of the Board of Directors of Intersect ENT, Inc., as a member of the Audit Committee of the Board, and as a member and the chairperson of the Nominating and Corporate Governance Committee of the Board, effective December 15, 2014. On December 9, 2014, the Board appointed Frederic H. Moll as a member of the Audit Committee of the Board to fill the vacancy created by Mr. Anderson's resignation. On December 8, 2014, Mark Fletcher tendered his resignation as a member of the Board of Intersect, effective December 15, 2014.

Similar Private Companies By Industry

Company Name Region
Orphan Medical Inc. United States
Consolidated Pharmaceutical Group, Inc. United States
Somnus Therapeutics, Inc. United States
Women's Capital Corp. United States
Canna-Pet, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Intersect ENT, Inc., please visit www.intersectent.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.